Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Dec 08, 2016
- Award recognizes scientific innovation of first approved drug for underlying cause of nonsense mutation Duchenne muscular dystrophy -
Additional Formats
Nov 18, 2016
SOUTH PLAINFIELD, N.J. , Nov. 18, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that on November 17, 2016 it approved non-statutory stock options to purchase an aggregate of 33,600 shares of its common stock to eight new employees.
Additional Formats
Nov 11, 2016
--PTC to conduct a post-authorization clinical trial --
Additional Formats
Nov 02, 2016
- Record quarter with Translarna™ net sales of $22M; 125% year-over-year growth -
- YTD Translarna net sales of $56M; on track for $65M to $85M full year guidance -
- Successful pricing and reimbursement negotiations concluded in Italy and Romania -
- CHMP opinion regarding Translarna's EMA marketing renewal expected by year-end -
- SMA program advancing with Phase 2 SUNFISH study initiated in Type 2/3 patients -
Additional Formats
Oct 20, 2016
- Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients -
- FIREFISH study in Type I SMA patients expected to begin in the coming months -
Additional Formats
Oct 19, 2016
SOUTH PLAINFIELD, N.J. , Oct. 19, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Wednesday, November 2,
Additional Formats
Oct 17, 2016
SOUTH PLAINFIELD, N.J. , Oct. 17, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today provided a regulatory update on Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). U.S. regulatory update PTC Therapeutics announced today that at the
Additional Formats
Oct 06, 2016
SOUTH PLAINFIELD, N.J. , Oct. 6, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced new data supporting the potential benefit of ataluren in preserving lung function in non-ambulatory nonsense mutation Duchenne muscular dystrophy patients (nmDMD).
Additional Formats
Oct 04, 2016
- Data published in the Proceedings of National Academy of Sciences (PNAS) -
- Results show ataluren targets the protein production machinery -
Additional Formats
Sep 12, 2016
SOUTH PLAINFIELD, N.J. , Sept. 12, 2016 /PRNewswire/ -- PTC Therapeutics , Inc. ( NASDAQ : PTCT) today announced that on September 8, 2016 it approved non-statutory stock options to purchase an aggregate of 22,900 shares of its common stock to eleven new employees.
Additional Formats